Improving Renal Cell Carcinoma Patient Outcomes with Multi-targeted TKIs and Immune Checkpoint Inhibitors – Enduring Webcast

Description

Program Description

---

Renal cell carcinoma (RCC) accounts for around 90 percent of kidney cancers. Early-stage renal cancers tend to have a better prognosis, while advanced cancers have a worse prognosis. Historically, approximately 25-30% of patients diagnosed with RCC had metastasis at diagnosis. However, due to the increased use of radiologic and ultrasound imaging techniques, incidental detection is more frequent, and more patients are diagnosed with Stage I–III (localized or loco-regional) disease. People with a strong family history of RCC may have a higher chance of developing it. Certain genetic conditions, including von Hippel-Lindau disease, may also increase the risk of developing RCC.

Intended Audience

---

Hematologists/oncologists, physician assistants, nurse practitioners, and nurses

Commercial Supporter

---

This activity is supported by an educational grant from Merck Sharp & Dohme and Exelixis Inc.